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Abstract
Aim: Optimal airway management during out-of-hospital cardiac arrest (OHCA) is uncertain. Complications from tracheal intubation (TI) may be
avoided with supraglottic airway (SGA) devices. The AIRWAYS-2 cluster randomised controlled trial (ISRCTN08256118) compared the i-gel SGA with
TI as the initial advanced airway management (AAM) strategy by paramedics treating adults with non-traumatic OHCA. This paper reports the trial cost-
effectiveness analysis.
Methods: A within-trial cost-effectiveness analysis of the i-gel compared with TI was conducted, with a 6-month time horizon, from the perspective of the
UK National Health Service (NHS) and personal social services. The primary outcome measure was quality-adjusted life years (QALYs), estimated
using the EQ-5D-5L questionnaire. Multilevel linear regression modelling was used to account for clustering by paramedic when combining costs and
outcomes.
Results: 9296 eligible patients were attended by 1382 trial paramedics and enrolled in the AIRWAYS-2 trial (4410 TI, 4886 i-gel). Mean QALYs to
6 months were 0.03 in both groups (i-gel minus TI difference -0.0015, 95% CI 0.0059 to 0.0028). Total costs per participant up to 6 months post-OHCA
were £3570 and £3413 in the i-gel and TI groups respectively (mean difference £157, 95% CI £270 to £583). Based on mean difference point
estimates, TI was more effective and less costly than i-gel; however differences were small and there was great uncertainty around these results.
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Conclusion: The small differences between groups in QALYs and costs shows no difference in the cost-effectiveness of the i-gel and TI when used as
the initial AAM strategy in adults with non-trauQ7 matic OHCA.
21 Keywords: Cost-effectiveness analysis, Out of hospital cardiac arrest, Airways management
22 Introduction
23 Up to 30,000 peoQ8 ple receive resuscitation following out-of-hospital
24 cardiac arrest (OHCA) in England each year, yet only 25% achieve a
25 return of spontaneous circulation (ROSC) and 8% are discharged
26 from hospital.1 Optimal cardiopulmonary resuscitation (CPR),
27 requiring a clear airway and uninterrupted chest compressions,
28 and early ROSC are key to avoid or minimise neurological
29 impairment in OHCA survivors.2,3 Early effective airway manage-
30 ment, to prevent and relieve airway obstruction is fundamental.
31 However, optimal airway management during OHCA is uncertain,
32 with little high-quality research to base treatment recommendations
33 on.4 Options range from basic airway intervention (e.g bag-mask
34 ventilation with or without airway adjuncts) to advanced procedures
35 such as inserting a supraglottic airway device (SGA) or tracheal
36 intubation (TI).5
37 Tracheal intubation has been considered the ‘gold standard’ way
38 to manage the airway during OHCA. However, this assumption is not
39 well supported by research evidence and not without risks, as
40 intubation attempts can cause interruptions to chest compressions.
41 SGAs are an alternative, and considered as quicker and easier to
42 insert, with fewer complications than TI.6 However, SGAs have not
43 been extensively tested, particularly in OHCA clinical trials.
44 Equipoise between the two techniques led to calls for a large
45 randomised controlled trial (RCT) comparing them.7,8 Relatively small
46 gains in survival of 23% would be clinically meaningful,9 providing
47 the technique is cost-effective.
48 AIRWAYS-2 was a cluster RCT designed to assess whether the i-
49 gel SGA is superior to TI in non-traumatic OHCA in adults, in terms of
50 clinical and cost-effectiveness. As OHCA is an extreme medical
51 emergency, it was not considered practical to randomise individual
52 patients. Therefore, paramedics were randomised and each treated
53 as a cluster. The trial recruited paramedics from four large emergency
54 medical service (EMS) provider organisations (ambulance services)
55 in England covering around 21 million people. 1523 paramedics
56 volunteered to participate and were randomised 1:1 to use the i-gel
57 SGA (759 paramedics) or TI (764 paramedics) as their initial
58 advanced airway management (AAM) strategy when attending adult
59 patients with non-traumatic OHCA. The trial primary outcome was
60 good functional outcome (modified Rankin Scale score of 03) at
61 hospital discharge or 30 days post-OHCA. 9296 eligible patients were
62 attended by 1382 trial paramedics and enrolled in the AIRWAYS-2 trial
63 (4410 TI, 4886 i-gel). Not all paramedics who volunteered attended an
64 OHA during the study period, hence the number attending is lower
65 than the numbers volunteering. The trial reported no difference in the
66 primary outcome between the groups (primary outcome was observed
67 in 6.8% and 6.4% of participants in the TI and i-gel groups,
68 respectively)10 This result supported the use of either airway
69 management strategy.
70 However, given pressure on healthcare systems, it is important to
71 consider the cost-effectiveness of treatment. We are not aware of
72 other trial-based cost-effectiveness analyses of alternative AAM
73strategies after non-traumatic OHCA. This paper reports the methods
74and results of the cost-effectiveness analysis for the AIRWAYS-2 trial.
75Methods
76The AIRWAYS-2 trial (ISRCTN08256118) collected detailed patient-
77level data on resource use and health-related quality of life (HRQoL) of
78participants. The trial methods and results are detailed
79elsewhere.10,11
80The economic evaluation was a within-trial cost-effectiveness
81analysis, with the main outcome measure being quality-adjusted life
82years (QALYs). Our analysis was conducted from a National Health
83Service (NHS) and personal social services perspective, as
84recommended by the UK National Institute for Health and Care
85Excellence (NICE).12 The time horizon was 6 months, starting when
86the first paramedic arrives at the OHCA scene. We anticipated most
87major resource use would occur within this timeframe as this included
88the ambulance, accident and emergency and intensive care and
89inpatient components.
90Resource use and costs
91Resource use data were collected on all NHS care resource episodes
92for trial participants to the six-month follow-up. Detailed resource use
93data on the pre-hospital phase of the patient care pathway were
94collected on the trial case report forms (CRFs); airway devices used
95and management at the scene, ambulance staff (and vehicles) that
96attended, and time spent with the patient. Following hospital arrival,
97data were largely obtained from Hospital Episode Statistics (HES)
98datasets, collected routinely in the NHS, supplemented by in-hospital
99trial CRFs. Resource use included emergency department atten-
100dance, length of stay by level of care, operations and procedures. For
101patients surviving to hospital discharge, hospital resource use
102(readmissions, outpatient or emergency department attendances)
103were obtained from HES; primary and community care resource use
104post hospital discharge were captured on bespoke follow up resource
105use questionnaires at three and six months post-OHCA, for
106participants who consented to follow up after hospital discharge.
107Although there was excellent case ascertainment for three of the
108HES datasets received (Accident and Emergency, Admitted Patient
109Care, Outpatients), there were fewer participants in the Critical Care
110dataset than expected, based on CRF data (<25% of those expected).
111Given this wide disparity between data sources, we did not use the
112HES Critical Care dataset and used time in intensive care captured on
113the CRFs instead.
114Unit costs to attach to healthcare resource use were largely from
115national sources; National Schedule of Reference Costs for ward
116costs, scans and surgery; and Unit Costs of Health and Social Care for
117community costs13,14 (Supplementary appendix 1). Resources were
118valued in 2017/18 pounds sterling, and costs not in 2017/18 prices
119were adjusted to 2017/18 prices using the NHS cost inflation index
120(NHSCII).15
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121 HRQoL and QALYs
122 The main outcome measure for the economic evaluation was HRQoL,
123 using QALYs estimated from, the EQ-5D-5L questionnaire.16,17 The
124 EQ-5D-5L was completed at three time points by participants who
125 consented to follow up: at hospital discharge (or 30 days-post OHCA if
126sooner), and at three and six months post-OHCA. Questionnaire
127responses were assigned valuations from published UK population
128tariffs, in line with NICE recommendations18,19; utility scores were
129then used to calculate QALYs.
130As OHCA is a medical emergency, and participants cannot
131complete the EQ-5D-5L at (or close to) the time of enrolment, baseline
Table 1 – Observed reso Q1urce use for patients known to be alive at each stage.
Resource use Randomised to TI (n = 4407) Randomised to i-gel (n = 4882) i-gel vs. TI




Advanced airway management devices used by A2 paramedic
TI
4138 (94) 0.94 (0.01)
4662 (96) 0.19 (0.01) 0.75 (0.78, 0.72)
i-gel
4138 (94) 0.33 (0.01)
4662 (96) 1.03 (0.01) 0.69 (+0.66, +0.73)
Other (OPA, NPA, LMA)
4138 (94) 0.47 (0.01)
4662 (96) 0.28 (0.01) 0.19 (0.23, 0.16)
Ambulance staff at scene (time in hours)c
Band 6 and above 4402 (100)
0.78 (0.03)
4873 (100) 0.82 (0.03) 0.04 (0.04, +0.13)
Band 5 4402 (100)
1.07 (0.03)
4873 (100) 1.07 (0.03) 0.00 (0.07, +0.08)
Band 4 4402 (100)
0.28 (0.01)
4873 (100) 0.26 (0.01) 0.02 (0.06, +0.02)
Band 2 or 3 4402 (100)
0.61 (0.01)
4873 (100) 0.63 (0.01) 0.02 (0.02, +0.06)
Total time 4402 (100)
2.73 (0.03)
4873 (100) 2.76 (0.03) 0.03 (0.06, +0.12)
Vehicles
Rapid response vehicle 4404 (100)
1.13 (0.02)
4878 (100) 1.14 (0.02) 0.01 (0.05, +0.06)
Ambulance 4404 (100)
1.23 (0.01)
4878 (100) 1.23 (0.01) 0.00 (0.03, +0.02)
Air ambulance 4404 (100)
0.10 (0.01)
4878 (100) 0.11 (0.01) 0.01 (0.01, +0.03)
Other 4404 (100)
0.13 (0.01)
4878 (100) 0.11 (0.01) 0.01 (0.04, +0.01)
Total 4404 (100)
2.59 (0.02)
4878 (100) 2.60 (0.02) 0.00 (0.04, +0.05)
Taken to hospital 1919 patients (44%) 2259 patients (46%)
ED attendanced 1919 (100)
0.99 (0.00)
2259 (100) 0.99 (0.01) 0.00 (0.00, +0.01)
Admitted to hospital 861 patients (20%) 1033 patients (21%)
Initial days in ICUe 861 (100) 3.87 (0.29) 1033 (100) 4.25 (0.22) 0.38 (0.34, +1.09)
Further days in ICUe 612 (71) 0.52 (0.11) 756 (73) 0.21 (0.06) 0.31 (0.56, 0.06)
Total days in hospital (includes ICU) 816 (95) 12.22 (0.84) 987 (96) 12.19 (0.86) 0.03 (2.38, +2.32)
Post hospital discharge (or 30 days if sooner) 377 patients (9%) 404 patients (8%)
Further inpatient days 352 (99) 2.46 (0.49) 383 (100) 2.01 (0.35) 0.46 (1.64, +0.73)
Further ED attendances 303 (98) 0.61 (0.08) 332 (99) 0.63 (0.06) 0.02 (0.17, +0.22)
OPT appointments 322 (99) 5.63 (0.49) 353 (99) 5.84 (0.35) 0.20 (0.99, +1.40)
GP contacts 106 (94) 4.21 (0.37) 105 (94) 3.34 (0.39) 0.87 (1.92, +0.18)
Nurse contacts 108 (94) 1.92 (0.26) 100 (94) 2.05 (0.49) 0.13 (0.96, +1.22)
Percentages are rounded to the nearest whole number.
A2 = AIRWAYS-2; CI = confidence interval; ED = emergency department; GP = general practitioner; ICU = intensive care unit; LMA = laryngeal mask airway;
NPA = nasopharyngeal airway; OPA = oropharyngeal airway; OPT = outpatient; SE = standard error; TI = tracheal intubation.
a ‘n’ is the number of participants with data for each resource use item.
b
‘mean number’ is the average use of a resource per participant.
c
‘Bands 26’ are NHS pay bands.
d 28 patients are admitted directly to a ward without going to ED (13 straight to ICU, 15 to a ward).
e “Initial days in ICU” captures ICU stay straight from ED or ambulance. If participants are discharged from there to a ward, but deteriorate and return to ICU, this is
captured in “Further days in ICU”.
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132 HRQoL (at the time of OHCA) data were not available. We assumed a
133 baseline EQ-5D value for all participants of 0.402, equivalent to the
134 unconscious health state for the EQ-5D-3L, in line with a published review
135 recommending including a constant or imputed baseline value (rather
136 than ignoring it).20 An alternative assumption of assuming a zero value,
137 the health state value for death, was explored in a sensitivity analysis.
138 The number of QALYs accrued by participants was calculated
139 assuming that a participant’s utility (from their EQ-5D data) changed
140 linearly between each of the time points (time of OHCA, hospital
141 discharge, and three and six months post-OHCA). The utility of
142 participants who died during the trial was assumed to change linearly
143 between the preceding time point and time of death, and take the value
144 of zero from death onwards.
145 Analysis methods
146 Analyses were performed on an intention-to-treat basis. Costs and
147 effects were not discounted as our time horizon was <12 months. We
148 summarised theamount of missingdata for resource use and outcomes
149 (EQ-5D scores) and explored why and how data might be missing.21
150 Multiple imputation was used to take account of missing data in
151 accordance with guidelines,21,22 (see Supplementary appendix 2).
152As AIRWAYS-2 was a cluster RCT, statistical methods for combining
153costs and outcomes needed to account for the correlation between costs
154and outcomes at the individual and cluster (paramedic) level.23 We used
155multilevel liner regression modelling to take account of the clusters, since
156this can also accommodate missing data and cost skewness.24
157The incremental cost-effectiveness ratio (ICER) is calculated as
158the incremental change (difference) in costs between groups divided
159by the incremental change in health outcome. Our ICER was derived
160from the average costs and QALYs (outcome) gained in each trial
161group, producing an incremental cost per QALY gained of the i-gel
162compared with TI. Non-parametric bootstrapping of costs and QALYs
163was used to examine uncertainty around the ICER (Appendix).
164Analyses were performed using Stata version 15.1 (StataCorp) and
165Microsoft Excel 2016.
166Presentation of results
167The mean costs and QALYs in each trial group, with standard errors
168(SEs) and 95% confidence intervals (CIs), are provided as well as the
169ICER. Uncertainty around the ICER is shown on the cost-effective-
170ness plane by the bootstrap replicates of the mean difference in costs
171and QALYs between the groups.
Table 2 – Observed costs for patients known to be alive at each stage.
Cost category Randomised to TI (n = 4407) Randomised to i-gel (n = 4882) i-gel vs. TI
na (%) Mean (SE) cost na (%) Mean (SE) cost Mean difference (95% CI)
Pre-hospital 4407 patients (100%) 4882 patients (100%)
Initial airway management devices
used pre A2 paramedic
4386 (100) £1 (0) 4859 (100) £1 (0) £0 (0, +0)
Advanced airway management
devices used by A2 paramedic
TI 3901 (89) £11 (0) 4607 (94) £2 (0) £9 (9, 8)
i-gel 4138 (94) £2 (0) 4662 (95) £5 (0) £3 (+3, +4)
Other (OPA, NPA, LMA) 4138 (94) £1 (0) 4662 (95) £0 (0) £1 (1, 1)
Total 3901 (89) £13 (0) 4607 (94) £7 (0) £6 (7, 6)
Ambulance staff at sceneb
Band 6 and above 4402 (100) £22 (1) 4873 (100) £23 (1) £1 (1, +4)
Band 5 4402 (100) £25 (1) 4873 (100) £25 (1) £0 (2, +2)
Band 4 4402 (100) £5 (0) 4873 (100) £5 (0) £0 (1, +0)
Band 2 or 3 4402 (100) £10 (0) 4873 (100) £10 (0) £0 (0, +1)
Total 4402 (100) £61 (1) 4873 (100) £62 (1) £1 (1, +3)
Vehicles 4404 (100) £146 (1) 4878 (100) £147 (1) £1 (2, +3)
Pre-hospital total 3890 (88) £221 (2) 4586 (94) £216 (2) £4 (9, +1)
Taken to hospital 1919 patients (44%) 2259 patients (46%)
ED attendance 1682 (88) £330 (3) 1994 (88) £327 (3) £3 (11, +6)
Admitted to hospital 861 patients (20%) 1033 patients (21%)
Index inpatient care 802 (93) £6802 (296) 974 (94) £6469 (269) £333 (1118, +452)
ICU days 612 (71) £7031 (538) 756 (73) £6931 (317) £99 (1323, +1124)
Post hospital discharge (or 30 days if sooner) 377 patients (9%) 404 patients (8%)
Further inpatient days 352 (99) £2082 (324) 383 (100) £1705 (207) £378 (1132, +377)
Further ED attendances 303 (98) £132 (16) 332 (99) £135 (13) £3 (37, +43)
OPT appointments 322 (99) £748 (54) 353 (99) £840 (60) £92 (67, +251)
GP contacts 106 (94) £111 (11) 105 (94) £86 (10) £26 (55, +3)
Nurse contacts 108 (94) £34 (6) 100 (94) £41 (14) £7 (23, +37)
A2 = AIRWAYS-2; CI = confidence interval; ED = emergency department; GP = general practitioner; ICU = intensive care unit; LMA = laryngeal mask airway;
NPA = nasopharyngeal airway; OPA = oropharyngeal airway; OPT = outpatient; SE = standard error; TI = tracheal intubation.
Percentages are rounded to the nearest whole number, and costs are rounded to the nearest pound.
a
‘n’ is the number of participants with data for each cost item.
b
‘Bands 26’ are NHS pay bands.
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172 Sensitivity analyses
173 Univariate sensitivity analyses (one variable at a time) examined the
174 impact on costs and cost-effectiveness results of variation in key
175 variables and major cost drivers. These were: unit costs for
176 paramedics, emergency department attendance, intensive care stay
177 and inpatient care, and the impact of excluding high-cost participants.
178 Factors varied for health outcomes were: the assumed baseline
179 quality of life (assuming a baseline utility of zero rather than 0.402);
180 and considering life years as an alternative outcome to QALYs
181 Multiple imputation was used to handle missing data (see Supple-
182 mentary appendix 2), and 25 imputations were conducted (see
183 Supplementary appendix 3).
184 Baseline variables (age, sex and ambulance trust) were included
185 in the regression models as they were significant predictors of missing
186 data. Our base case analysis included all trial participants, except
187 seven who were transported to hospital but could not be identified and
188 were lost to follow up (three TI, four i-gel), so there was insufficient
189 information to reasonably impute their follow up data (consistent with
190 trial effectiveness analyses).
191 Results
192 9296 eligible patients were attended by 1382 trial paramedics
193 between June 2015 and August 2017 and enrolled in the AIRWAYS-
194 2 trial (4410 TI, 4886 i-gel). Participants had a median age of 73 years,
195 and 36% were women. 21% of participants had some missing
196 resource use or outcome data (24% TI, 19% i-gel).
197 Resource use and costs
198 Since many participants die at the scene of their OHCA or in A&E,
199 Table 1 reports the observed resource use for participants known to be
200 alive at pre-hospital, taken to hospital, admitted to hospital or post
201 hospital discharge. Apart from the AAM strategy used, resource use at
202the scene was similar between the two groups. On average 2.7 h of
203paramedic time was spent per OHCA, with 23 vehicles attending. A
204slightly higher proportion of participants in the i-gel group were taken to
205hospital (46% compared with 44% in the TI arm, Table 1). For
206participants surviving to hospital admission, most were admitted to
207intensive care. Participants in the i-gel group spent slightly longer as
208inpatients and in intensive care than the TI group, but these
209differences are non-significant. Resource use for participants
210surviving to hospital discharge was similar between groups.
211Table 2 presents the observed costs for participants known to be
212alive at each stage. Costs were similar between the groups for
213participants who were alive. The airway devices are inexpensive, and
214costs associated with them small.
215A breakdown of total costs for all participants (based on imputed
216data) is provided in Fig. 1. Total mean (average) costs (SE) were £
2173570 (£152) and £3413 (£162) in the i-gel and TI groups respectively
218(mean difference £157, 95% CI £278 to £592). Despite only 20% of
219participants being admitted to hospital, the key cost drivers are
220inpatient stay and time in intensive care. Since more participants in the
221i-gel group were transported to hospital, hence, spending slightly
222longer in hospital and in intensive care, these costs are slightly (non-
223significantly) higher in the i-gel group; mean (SE) combined inpatient
224and intensive care costs for the index admission were £2938 (£142)
225and £2746 (£148) in the i-gel and TI groups respectively (mean
226difference £192, 95% CI £210 to £593). However, costs are similar
227between the groups.
228HRQoL and QALYs
229There is little difference in mean observed EQ-5D scores between the
230groups at the three time points, resulting in a small (non-significant)
231difference in observed QALYs (Table 3, and similar patterns based on
232imputed data, in Supplementary appendix 4). The QALYs gained in
233each group are small, influenced by the large proportion of participants
234who die early in the trial. The actual difference in QALYs to 6 months is
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Fig. 1 – Breakdown of total costs to six months for all participants in each treatment group.
TI = tracheal intubation.
The error bars represent the 95% confidence interval around total costs in each treatment group.
Mean cost components in this figure are unadjusted for cluster, as some components were not estimable.
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236 Cost-effectiveness
237 The differences in costs and QALYs between the groups are small and
238 neither difference is statistically significant (Table 4). The difference
239 between the groups for QALYs is especially small, creating a really large
240 ICER, because the difference in QALYs is the denominator for
241 calculating the ICER. Based on the point estimate of the ICER
242 (£102,362), TI is considered cost-effective, being more effective and
243 less costly than i-gel; in health economic terms TI is thereforeconsidered
244 “dominant” over i-gel. However, there is much uncertainty around this
245 result, as shown on the cost-effectiveness plane (Fig. 2), where the
246bootstrap replicates of the cost and QALY differences cover three
247quadrants of the plane. The black dot is the point estimate of the cost and
248QALY difference, and is close to the origin. The small non-significant
249differences and the large number of points over three quadrants indicate
250there is no evidence of a difference in cost-effectiveness between the
251two groups. This suggests that if a decision-maker is willing to pay
252£20,000 for an additional QALY, then the probability of the i-gel being
253cost-effective is 18%. The probability that the i-gel is cost-effective is low
254across all willingness to pay thresholds from £0 to £100,000, and
255gradually reduces as the threshold is increased (from 23% to 7%),
256becoming less likely that the i-gel would be cost-effective.
Table 3 – Observed EQ-5D scores and QALYs to 6 months.
Outcome Randomised to TI (n = 4407) Randomised to i-gel (n = 4882) i-gel vs. TI
n (%) Mean (SE) n (%) Mean (SE) Mean difference (95% CI)
EQ-5D time pointa
Hospital discharge (or 30 days) 4200 (95) 0.027 (0.002) 4662 (95) 0.024 (0.002)
0.002 (0.008, +0.003)
3 months 4195 (95) 0.026 (0.002) 4636 (95) 0.023 (0.002)
0.003 (0.009, +0.003)
6 months 4214 (95) 0.029 (0.002) 4661 (95) 0.026 (0.002)
0.003 (0.009, +0.003)
QALYs to 6 months 4153 (94) 0.0100 (0.0010) 4601 (94) 0.0088 (0.0009)
0.0012 (0.0037, +0.0013)
CI = confidence interval; SE = standard error; TI = tracheal intubation; QALY = quality-adjusted life-year.
a Deaths included as zero.
Table 4 – Base case cost-effectiveness results.
Cost-effectiveness element Randomised to TI (n = 4407) Randomised to i-gel (n = 4882) i-gel vs. TI difference
Total costs (95% CI)a £3413 (£3112, £3714) £3570 (£3279, £3860) £157 (£270, +£583)
QALYs (95% CI)a 0.0274 (0.0243, 0.0305) 0.0259 (0.0230, 0.0287) 0.0015 (0.0059, +0.0028)
ICER (Cost/QALY) TI dominant (£102,362)
CI = confidence interval; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year; TI = tracheal intubation.



















Fig. 2 – Cost-effectiveness plane.
QALY = quality-adjusted life-year.
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257 Sensitivity analyses
258 Sensitivity analyses (Supplementary appendix 3) shows that
259 conclusions were robust to changes in unit costs, to assuming a
260 baseline utility of 0 rather than 0.402 and to using life-years instead
261 of QALYs as an alternative outcome measure. Nine high-cost
262 participants (total costs exceeding £100,000) have a significant
263 impact on the cost results, but do not alter the conclusions.
264 Discussion
265 There was very little difference between the groups for costs or
266 effects, and great uncertainty around the cost-effectiveness results.
267 Total costs were slightly higher in the i-gel group, due to being in
268 intensive care slightly longer. Despite only 20% of participants
269 surviving to hospital admission, inpatient and intensive care costs
270 were the key drivers of total costs. The QALYs gained were similar in
271 both groups and small (because of the large number of patients who
272 died early in the trial) and not statistically significantly different.
273 There is no evidence of a difference in cost-effectiveness between
274 groups. Based on the point estimate of cost-effectiveness only, TI
275 was more effective and less costly than the i-gel (i.e. “dominant”)
276 and, therefore, cost-effective. However, we need to consider the
277 variability around the differences in costs and effects not just the
278 point estimate, and bootstrap replicates of these differences which
279 consider uncertainty, covered three quadrants of the cost-effective-
280 ness plane, showing substantial uncertainty around these results
281 and in reality there is no evidence of any difference between groups.
282 These conclusions on cost-effectiveness held after sensitivity
283 analyses.
284 This economic evaluation was an integral part of the largest RCT of
285 airway management in OHCA to date, which incorporated automatic
286 enrolment of all eligible patients to minimise bias.10,25 We collected
287 HRQoL data to six months, longer than most clinical trials in OHCA
288 and exceeded the minimum of 90 days recommended in the core
289 outcome set for cardiac arrest.26 We believe this is the first trial-based
290 cost-effectiveness analysis of an SGA with TI for first AAM for adults
291 with non-traumatic OHCA. The recent Pragmatic Airway Resuscita-
292 tion Trial (PART) of North American patients with OHCA compared the
293 laryngeal tube SGA with TI in 3004 patients, but did not include an
294 economic evaluation.27
295 Our economic evaluation has limitations. First, we were reliant on
296 questionnaire completion at the three-and six-month follow up (EQ-5D
297 data and primary and community healthcare resource use). Despite
298 considerable effort by the research teams, only 52.4% of survivors
299 consented to active follow up. This may have been due to a lack of
300 perceived benefit from participation, since the intervention had
301 already occurred, or may reflect patient health. However, the
302 proportion of missing data is similar across the two groups, with no
303 evidence that the availability of follow-up data was influenced by
304 patient allocation.
305 Second, there was a slightly larger proportion of participants in the
306 i-gel group surviving to ICU admission (TI, 19.5%; i-gel, 21.2%).
307 Although this did not translate into an improvement in the primary
308 outcome of good recovery (TI, 6.8%; i-gel, 6.4%) or a significant
309 improvement in any of the outcomes measured in AIRWAYS-2,10 this
310 does result in slightly higher average costs per participant in the i-gel
311 group for ICU and hospital stay. This means that i-gel may appear
312 slightly less cost effective than TI, however there is a high degree of
313uncertainty, and neither approach is clearly superior. Whilst additional
314survival to hospital and ICU admission alone were not considered
315clinically beneficial in this trial, hospital admission is the first step on
316the journey to a successful outcome (long-term high-quality survival),
317and may improve the experience of families by providing additional
318time to say goodbye to their relative.
319Third, we used some secondary care data collected routinely.
320Thus, despite AIRWAYS-2 being one of the largest health economic
321analyses of OHCA patients completed, there was minimal data
322collection burden on paramedics and local hospital teams. However,
323when the datasets arrived there was poor case ascertainment in the
324Critical Care dataset. Given that intensive care costs were a key driver
325of total costs, this was disappointing.
326Fourth, given that participants are severely incapacitated at
327enrolment, baseline HRQoL could not be collected. This could
328introduce bias into QALY estimation if randomisation is unbalanced
329between treatment groups. Whilst a published review concluded that
330there is no one clear way of dealing with this,20 it recommended
331including a constant or imputed baseline value, and collecting HRQoL
332as early as possible post randomisation, in line with our approach.
333Finally, we did not include training costs for either treatment. As
334tracheal intubation training costs are likely to be higher than i-gel costs
335(more complex procedure), this may have underestimated the costs of
336these devices.
337Conclusions
338There is no health economic evidence to suggest a difference in cost-
339effectiveness between the two AAM strategies, as there were tiny
340(non-significant) differences between the groups in costs and effects,
341and substantial uncertainty around cost-effectiveness results.
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